WYZGA MICHAEL S 4

What Happened

• Michael S. Wyzga, a director of Mereo BioPharma Group plc (MREO), received a derivative award of 66,000 shares on February 26, 2026. The filing shows a price of $0.00 (i.e., a grant/award rather than a purchase) and does not report a cash value for the award. This is a compensation/retention grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-26; Form 4 filed 2026-02-27 (timely).
• Amount granted: 66,000 shares (transaction code A — award/grant). Price reported: $0.00.
• Vesting: Vests in substantially equal monthly installments over one year from the grant date (see footnote).
• ADS note: Footnote states each American Depositary Share (ADS) represents five ordinary shares. If the grant is denominated in ADS, 66,000 ADS would equal 330,000 ordinary shares (filing language should be checked for whether the grant is ADS or ordinary shares).
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding, or late-filing flags noted in the provided information.

Context

• This is a compensation award (derivative grant) that vests over time, so it does not represent an immediate cash investment or sale by the insider. Such grants are common for executive/director compensation and primarily signal retention/incentive rather than a direct view on near-term stock direction.